Hub: https://www.merlintrader.com/celc-celcuity-inc/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=celc
Not investment advice.
Hub: https://www.merlintrader.com/celc-celcuity-inc/?utm_source=bluesky&utm_medium=social&utm_campaign=flyer-q3-2026&utm_content=celc
Not investment advice.
Hub: https://www.merlintrader.com/celc-celcuity-inc/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
Hub: https://www.merlintrader.com/celc-celcuity-inc/
Newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13
https://www.stocktitan.net/news/CELC/celcuity-announces-fda-acceptance-of-s-nda-for-revtorpyktm-aqro7lxzfbcd.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-announces-fda-acceptance-of-s-nda-for-revtorpyktm-aqro7lxzfbcd.html?utm_source=stocktitan-bluesky&utm_medium=social
Off-exchange (dark pool) shares, % of volume: Nov 10 407,785 (53.0%).
Read the full article for the full details.
#optionsflow #stocks #optionstrading #stockmarket
Off-exchange (dark pool) shares, % of volume: Nov 10 407,785 (53.0%).
Read the full article for the full details.
#optionsflow #stocks #optionstrading #stockmarket
https://www.stocktitan.net/news/CELC/celcuity-inc-reports-third-quarter-2026-financial-results-and-crzztf0upkwl.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-inc-reports-third-quarter-2026-financial-results-and-crzztf0upkwl.html?utm_source=stocktitan-bluesky&utm_medium=social
https://fundspec.ai/s/CELC/earnings
Screen valuation, momentum and options flow together in one place.
https://fundspec.ai/s/CELC/earnings
Screen valuation, momentum and options flow together in one place.
On November 05, 2026, Celcuity Inc. issued a press release regarding the Company’s financial results for the quarter ended September 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
On November 05, 2026, Celcuity Inc. issued a press release regarding the Company’s financial results for the quarter ended September 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
CEO Brian Sullivan speaks on Nov 10, Nov 11 and Nov 18.
Shares closed at $67.07 Mon: below SMA50, below SMA200, RSI 45.
Hub: www.merlintrader.com/celc-celcuit...
Not investment advice.
CEO Brian Sullivan speaks on Nov 10, Nov 11 and Nov 18.
Shares closed at $67.07 Mon: below SMA50, below SMA200, RSI 45.
Hub: www.merlintrader.com/celc-celcuit...
Not investment advice.
https://www.stocktitan.net/news/CELC/celcuity-schedules-release-of-third-quarter-2026-financial-results-vxubze4rk26d.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-schedules-release-of-third-quarter-2026-financial-results-vxubze4rk26d.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-o7y5whwtg4p3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-o7y5whwtg4p3.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.merlintrader.com/celc-celcuity-inc/
https://www.merlintrader.com/celc-celcuity-inc/
https://www.stocktitan.net/news/CELC/celcuity-presents-updated-data-from-a-phase-1b-2-study-evaluating-to7uh3a5ires.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CELC/celcuity-presents-updated-data-from-a-phase-1b-2-study-evaluating-to7uh3a5ires.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.merlintrader.com/celc-celcuity-inc/
https://www.merlintrader.com/celc-celcuity-inc/
https://www.merlintrader.com/celc-celcuity-inc/
https://www.merlintrader.com/celc-celcuity-inc/
October 19, 23 & 24, 2026 — ESMO Abstracts & Clinical Data
Oct 19: ESMO abstracts (VIKTORIA-1 LBA16). Oct 23: Phase 1b gedatolisib prostate cancer data. Oct 24: VIKTORIA-1 subgroups.
🔗 Full details: www.merlintrader.com/celc-celcuit...
#CELC #Biotech #ESMO2026
October 19, 23 & 24, 2026 — ESMO Abstracts & Clinical Data
Oct 19: ESMO abstracts (VIKTORIA-1 LBA16). Oct 23: Phase 1b gedatolisib prostate cancer data. Oct 24: VIKTORIA-1 subgroups.
🔗 Full details: www.merlintrader.com/celc-celcuit...
#CELC #Biotech #ESMO2026